Bioray Laboratories
Clinical trials sponsored by Bioray Laboratories, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- One-Shot gene fix for blood disorder enters human testing Results expected Oct 2026 (estimated)
- New CAR-T therapy targets Hard-to-Treat lymphoma Results expected Nov 2026 (estimated)
- New CAR t therapy targets Hard-to-Treat blood cancer Results expected Mar 2027 (estimated)
- Off-the-Shelf cell therapy takes on tough lymphoma Results expected Aug 2027 (estimated)
-
Gene therapy aims to free patients from lifelong blood transfusions
Cure Recruiting nowThis study follows people who have already received an experimental gene therapy called BRL-101 for transfusion-dependent β-thalassemia, a severe blood disorder requiring regular transfusions. Researchers will monitor participants over the long term to check for safety issues, su…
Sponsor: Bioray Laboratories • Aim: Cure
Last updated Jul 23, 2026 00:00 UTC
-
New CAR t therapy targets Hard-to-Treat blood cancer
Disease control Recruiting nowThis early study tests a new treatment called BCMA-UCART for adults with multiple myeloma that has come back or stopped responding to other therapies. The treatment uses donor immune cells that are specially designed to find and attack cancer cells. The main goals are to see if t…
Sponsor: Bioray Laboratories • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New CAR-T therapy targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-stage study tests a new treatment called BRL-201 for people with relapsed or refractory B-cell non-Hodgkin lymphoma. The therapy uses a patient's own immune cells, modified to target cancer cells, and aims to control the disease. About 12-18 adults will participate to …
Phase 1 • Sponsor: Bioray Laboratories • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Off-the-Shelf cell therapy takes on tough lymphoma
Disease control Recruiting nowThis early study tests a one-time treatment using universal (off-the-shelf) CAR-T cells that target CD19, a protein on cancer cells. It is for adults with relapsed or refractory B-cell non-Hodgkin lymphoma who have few options left. The main goal is to check safety and find the r…
Sponsor: Bioray Laboratories • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC